James S. Burns, president and chief executive officer of EntreMed
Inc. (ENMD), will preside over the closing bell. The event will
mark the beginning of an exciting transitional period for the
company. EntreMed is moving forward with multiple mid-stage clinical
trials and expects to report clinical results for its two leading
oncology drug candidates throughout the year.
